Frequently Asked Questions
When should I expect my order to arrive?
Apothecary orders are fulfilled within 3-5 business days. Orders are shipped from New York, and transit times depend on the final destination.
Do you ship orders outside of the U.S.?
Orders on this site is processed only within the U.S. If you are ordering internationally, please email us to place an order.
What is your return / refund policy?
All sales are final.
How might I collaborate with Mind Weave?
If you are interested in collaborating (i.e. on events, custom products for your organization, or stocking Mind Weave products at your store), please email for more info!
What are common psilocybin doses?
The threshold dose for feeling the effects from dried mushrooms is typically in the 0.2g - 0.5g range, though it varies for each individual due to body weight and metabolism, as well as the variety and storage conditions of the mushrooms. A moderate dose in the 1.0g - 2.5g range typically produces a range of psychedelic effects that last from four to six hours. Doses over 3g can produce intense psychedelic effects and can introduce a higher potential for challenging experiences such as feelings of fear and anxiety. Ethnobotanist Terence McKenna popularized the term “heroic dose” in the 1980s in reference to 5g of dried mushrooms, but please note that an increase in dosage does not correlate with an increase in therapeutic benefits. Microdoses can range from 0.02g to 0.5g.
Can psilocybin be detected in a drug test?
Psilocybin and its metabolites are not included in most standard drug screens; however, they are sometimes included in extended drug screens.
What might people typically experience when macrodosing?
Literature reports feelings of love and forgiveness, personal epiphanies, euphoria, increased creativity, intense emotions, and heightened spirituality. There can also be visual distortions such as tracers and fractal geometries, increased vibrancy of colors, and shifting colors. Psychedelic mushrooms can also cause individuals to see and hear things that are not there, to experience synesthesia, and to reimagine their conventional sense of time.
Challenging experiences from a high dose can sometimes include increased anxiety and panic, fear and paranoia, confusion or disorientation, nausea, dry mouth, impaired judgment, and challenging visual hallucinations. If you experience these things, it’s usually best to remain calm, change your focus, and know that the experience will pass.
Why do some people microdose with psilocybin?
Many individuals who have integrated microdosing mushrooms into their weekly routine report higher levels of creativity, more energy, increased focus, and improved relational skills, as well as reduced anxiety, stress, and even depression. Some also report that microdosing mushrooms has helped them heighten their spiritual awareness and enhance their senses. Because microdosing is typically designed to be sub-perceptual, individuals do not expect psychedelic visual experiences or dramatically altered states of perception.
How safe is psilocybin?
TLDR: very safe
The lethal dose from psilocybin toxicity alone is unknown at recreational or medicinal levels, and has rarely been documented. As of 2011, only two cases attributed to overdosing on hallucinogenic mushrooms (without concurrent use of other drugs) have been reported in the scientific literature and may involve other factors aside from psilocybin. In rats, the median lethal dose for psilocybin administered orally is 280 milligrams per kilogram. Reaching this theoretical lethal dose in a 130 lb person would require ingesting 3.7 lb of dried mushrooms, or 37 lb of fresh mushrooms. This is roughly 1000 times greater than the quantity required for effective mental health treatment.
​
Psilocybin is not considered to be addictive nor does it cause compulsive use. One reason is that the macrodose experience, which can be physically and mentally challenging, may cause people using psilocybin to limit their frequency of use. Another reason is that the human body quickly builds tolerance to psilocybin, such that people require much higher doses after only a few days of repeated use. When compared to other substances in terms of fatal overdose potential and dependence potential, psilocybin is one of the safest entheogenic substances.
Common physical side effects of macrodosing can include an increase in heart rate and an increase in blood pressure. While these temporary effects generally last as long as the trip does (4 - 6 hours), the potential increases in blood pressure can be a risk factor for users with pre-existing hypertension.
There are no studies that investigate the impact of psilocybin on pregnancy and breastfeeding. As such, some individuals may choose to avoid the intake of psilocybin during pregnancy and up to three months after giving birth.
Panic reactions can occur after the ingestion of psychedelic mushrooms, especially if the user does not prepare their expectations or accidentally ingests the substance. Other adverse effects less frequently reported include temporary paranoia, confusion, prolonged derealization (disconnection from reality), and mania. Usage by those with schizophrenia can induce acute psychotic states requiring hospitalization.
​
Taking lithium, Tramadol or Ritonavir together with psychedelics can sometimes cause seizures, tremors, heart damage, delirium, and other unpredictable negative effects. St. John’s wort, SSRIs, SNRIs, MAOIs, or any other antidepressants, as well as triptans migraine medications, can diminish the effects of psychedelics.
​
While conducting a study of 500 individuals who microdosed on LSD, Dr. Fadiman noticed that five participants who all shared red/green colorblindness dropped from the study due to seeing tracers (the glowing trails that follow moving objects typically experienced by people tripping on effective doses of psychedelics). While this has not yet been confirmed with psilocybin – nor is the mechanism understood at all – those with red/green colorblindness might exercise caution when approaching microdosing.
Understanding Psilocybin
Psilocybin
3-[2-(Dimethylamino)ethyl]-1H-indol-4-yl dihydrogen phosphate
​
C
12
H
17
2
4
N
O
P
Overview:
Psilocybin is a naturally occurring psychedelic compound found in certain species of mushrooms, commonly known as "magic mushrooms." Over the past few decades, there has been a growing interest in the potential therapeutic benefits of psilocybin, particularly in the betterment of a variety of treatment-resistant mental health conditions. Currently, research on psilocybin is ongoing in various areas, including clinical trials, basic neuroscience research, and ethnobotanical studies.
The clinical research is focused on investigating the safety and efficacy of psilocybin-assisted therapy for various mental health conditions, with many studies showing promising results. One of the most well-known and widely cited studies on psilocybin-assisted therapy was conducted at Johns Hopkins University, where researchers found that a single high dose of psilocybin produced substantial decreases in depression and anxiety in patients with life-threatening cancer. More recently, a study has shown that the substantial antidepressant effects of psilocybin-assisted therapy may be durable at least through 12 months. Other studies have also shown promising results in helping people integrate addictions (especially alcohol and tobacco) as well as helping people with post-traumatic stress disorder (PTSD).
​
In addition to clinical research, there is also a growing body of basic neuroscience research on psilocybin. This research is aimed at understanding the neural mechanisms underlying the effects of psilocybin, including how it interacts with the brain's serotonin system to produce its psychedelic effects and potential therapeutic benefits. This field, including studies relating psilocybin intake to neurogenesis, is still in its infancy.
​
Finally, there is also ongoing research in ethnobotany, which aims to understand the cultural and historical use of psilocybin-containing mushrooms in various indigenous communities around the world. Prehistoric rock art near Villar del Humo in Spain suggests that Psilocybe Hispanica was used in religious rituals 6,000 years ago. Other hallucinogenic varieties of Psilocybe mushrooms have a history of use among the native peoples of Mesoamerica for religious communion, divination, and healing, from pre-Columbian times to the present day. The first mention of hallucinogenic mushrooms in European medicinal literature was in the London Medical and Physical Journal in 1799. In 1955, Valentina Pavlovna Wasson and R. Gordon Wasson became the first known European Americans to actively participate in an indigenous mushroom ceremony. The first psychedelic boom in the 1960s was a novelty only for the West. Countless other cultures, especially Indigenous nations, have been well acquainted with a large number of psychedelic or entheogenic plants and medicines for millenia.
​
Overall, the current research landscape and plethora of community accounts on the benefits of psilocybin is incredibly promising. While the majority of research is focused on hallucinogenic dosages (macrodoses), many people choose to take unnoticeable & sub-perceptual dosages (microdoses) and report a similar degree of personal growth. Ultimately, more research is needed to fully understand the safety and efficacy of psilocybin, as well as any potential risks and limitations.
​
Arguably the riskiest thing about psilocybin is its potentially illegal nature. In the United States, it is federally classified as a Schedule I controlled substance. Psilocybin is decriminalized in Seattle, Washington; Ann Arbor, Michigan; Oakland and Santa Cruz, California; Somerville and Cambridge, Massachusetts; Oregon; and Washington D.C. Psilocybin is legal for therapeutic purposes in Colorado. In early 2023, New York lawmakers introduced a bill that if passed would fully legalize psilocybin and other hallucinogenic substances.
​